

## **Company Profile for Dynavax Technologies**

Feb 27, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops a diversified pipeline of novel Toll-like Receptor (TLR) based product candidates. Based on Dynavax's proprietary technologies, these products specifically modify the innate immune response to infectious, respiratory, autoimmune, and inflammatory diseases. Dynavax has partnerships with leading pharmaceutical companies such as GlaxoSmithKline, AstraZeneca AB, and Novartis as well as funding from Symphony Dynamo, Inc. and the National Institutes of Health. For more information visit <a href="https://www.dynavax.com">www.dynavax.com</a>.

Company: Dynavax Technologies

Headquarters Address: 2929 Seventh Street, Suite 100

Berkeley, CA 94710

Main Telephone:510-848-5100Website:www.dynavax.comTicker:DVAX(NASDAQ)

Type of Organization: Public

Industry: Biotechnology
Key Executives: CEO: Dino Dina

CFO: Deborah Smeltzer

**Investor Relations** 

**Contact:** Amy Figueroa **Phone:** 510-848-5100

Email: <a href="mailto:afigueroa@dynavax.com">afigueroa@dynavax.com</a>

SOURCE: Dynavax Technologies Corporation

Copyright Business Wire 2009